Similar articles

• ACP Journal Club. Review: PSA-based screening does not reduce prostate cancer mortality or all-cause mortality.

  Dahm P. Dahm P. Ann Intern Med. 2012 Apr 17;156(8):JC4-02. doi: 10.7326/0003-4819-156-8-201204170-02002. Ann Intern Med. 2012. PMID: 22508742 No abstract available.
• ACP Journal Club. Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality.

  Hoffman RM. Hoffman RM. Ann Intern Med. 2012 Jul 17;157(2):JC2-4. doi: 10.7326/0003-4819-157-2-201207170-02004. Ann Intern Med. 2012. PMID: 22801696 No abstract available.
• ACP Journal Club. Annual screening for prostate cancer did not reduce mortality from prostate cancer.

  Canfield SE. Canfield SE. Ann Intern Med. 2009 Jun 16;150(12):JC6-4, JC6-5. doi: 10.7326/0003-4819-150-12-200906160-02004. Ann Intern Med. 2009. PMID: 19528549 No abstract available.
• Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.

  Lim LS, Sherin K; ACPM Prevention Practice Committee. Lim LS, et al. Am J Prev Med. 2008 Feb;34(2):164-70. doi: 10.1016/j.amepre.2007.10.003. Am J Prev Med. 2008. PMID: 18201648 Review.
• Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.

  Hernández J, Thompson IM. Hernández J, et al. Cancer. 2004 Sep 1;101(5):894-904. doi: 10.1002/cncr.20480. Cancer. 2004. PMID: 15329895 Review.